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 Introduction
Urinary tract infection (UTI) is one of the most common bacterial infections in children. 
Recurrent UTI (rUTI) occur in about one-third of these patients.1 Children with rUTI are at 
risk of renal scarring leading to renal failure in the long term.2 Prevention often entails 
months to years of daily antibiotics. This strategy has variable success in reducing 
recurrence and invariably results in an increased risk of subsequent drug-resistant 
infections.3, 4
Two primary sources for rUTI have been proposed. First, the intestinal and vaginal tracts 
have been well established as reservoirs for uropathogenic bacteria such as Escherichia coli 
that recurrently ascend into the urinary tract via the urethra. Probiotic organisms may alter 
the intestinal and vaginal tract flora to reduce or resist pathogens. The probiotic yeast 
Saccharomyces boulardii has been shown to significantly reduce the intestinal burden of 
uropathogenic E. coli in children between 1.5 and 16 years of age.5 Treatment with this 
probiotic may therefore also help in reducing the risk of rUTI.
Second, among subjects with prior UTI, recurrent infections may arise from bacteria that are 
latent within the bladder epithelium. Common uropathogens such as Escherichia coli and 
Klebsiella pneumoniae have been shown to invade bladder epithelial cells and rapidly 
proliferate within intracellular bacterial communities (IBCs). 6–8 In the late stages of acute 
cystitis as modeled in mice, the bacteria enter into quiescent foci in the bladder epithelium 
where they may persist for months and reemerge to produce recurrent infections. Most of the 
traditional antibiotics fail to penetrate the epithelium and eradicate these quiescent 
intracellular bacteria. However, fluoroquinolones such as ciprofloxacin, given at sufficient 
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doses and time of exposure, have intracellular accumulation above minimal inhibitory levels 
to eradicate intracellular E. coli.9
Children with normal urinary tract anatomy and function and highly recurrent UTI suffer 
from a lack of alternatives when antibiotic prophylaxis and “watchful waiting” approaches 
fail. Our pediatric urology and infectious diseases clinics have a large number of children 
who have failed these standard approaches to rUTI prevention. To fill this gap in medical 
care, we previously instituted a prophylactic strategy using the otherwise benign 
fluoroquinolone-probiotic combination with the goal of targeting the aforementioned 
mechanisms of recurrent infections. We now retrospectively reviewed the outcomes of ten of 
the first children receiving this combination therapy in an attempt to quantify a reduction in 
rUTI that was perceived by both clinicians and patient families.
 Methods
After IRB approval, all patients previously managed with a fluoroquinolone-probiotic 
combination in the Pediatric Infectious Diseases clinic for rUTIs were identified. Their 
regimen included a 14-day course of ciprofloxacin (20 mg/kg) twice daily and 1 packet (250 
mg) of Saccharomyces boulardii daily for 1 year. All patients were advised to consume one 
particular brand of the yeast in order to ensure that all patients received similar therapy. Prior 
to referral, all patients obtained a thorough evaluation by a pediatric urologist. In addition to 
the studies noted in Table 1, bladder and bowel dysfunction was assessed in all patients by 
using a validated dysfunctional elimination syndrome questionnaire.10 In addition, stool 
character was quantified by documentation of the Bristol Scale. Patients were noted to be on 
stable bowel regimens for constipation prior to institution of the combination UTI 
prophylaxis regimen. Patients with symptoms of constipation were maintained on their 
bowel care regimen consisting of dietary changes to increase fiber intake and/or a stool 
softener. Compliance with bowel care and fluoroquinolone-probiotic regimen was 
determined by clinicians at outpatient visits approximately every 3 months by parental report 
of missed doses and tolerance of the regimen. Their medical charts were retrospectively 
evaluated for confirmation of a diagnosis of rUTI (>1 episode of a complicated or 
uncomplicated UTI within a year and at least 1 episode with records available to confirm a 
positive urinalysis (positive [leukocyte esterase OR nitrite] AND [≥5–10 WBC]) and a 
positive urine culture (≥50,000 CFU/ml), results of urologic evaluation, and absence of 
predisposing conditions (neurogenic bladder, VUR, spinal dysraphism) for inclusion. 
Patients with a history of voiding dysfunction or constipation were continued on their 
regimens. Patients with follow-up of <3 months were excluded.
 Results
Ten patients referred to our clinic with a history of recurrent UTI met inclusion criteria. 
Their mean age was 8.2 years old (range 4–13). The mean number of UTIs in the year prior 
to initiation of therapy was 5.5 (range 2–10). No anatomical urologic abnormalities were 
noted on urologic evaluation (Table 1). All patients reported soft, regular stools with 80% 
taking maintenance medications for constipation. The most common reported symptom and 
sign from prior UTIs were dysuria and fever, respectively.
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After institution of the antibiotic-probiotic combination, the median follow-up was 9 months 
(range 3–15). Four episodes of on-treatment recurrent UTI occurred among 3 patients, 2 of 
whom had reported therapeutic non-compliance. Among the patients with on-therapy 
recurrences, median follow-up was 10 months. Median follow-up in patients without rUTI 
was 7 months. It should be noted that each patient was followed well past their previously 
recorded average interval period between UTI episodes. There was a highly significant 
decrease in the total number of UTI episodes in all 10 patients before and after initiation of 
therapy (57 vs. 4; p=0.0001). In our cohort, 7 out of 10 patients (70%) were free of rUTIs 
during the follow-up period. Of the patients with known compliance, 7 out of 8 were free of 
rUTIs (88%).
Urinalysis and culture data prior to the initiation of therapy (where available) and with rUTI 
are reported in Table 2. Data were available for UTI episodes where care was obtained 
within the study health system. Prior to initiation of therapy, the most common UTI etiology 
was E. coli, followed by K. pneumonia, and P. aeruginosa. These pathogens had variable 
sensitivity to β-lactams but were uniformly sensitive to fluoroquinolones. Antibiotic 
susceptibility data were not available prior to therapy for 2 subjects. On-therapy rUTIs were 
due to E. coli (2; fluoroquinolone susceptibility unknown), enterococcus (1), and C. freundii 
(1; fluoroquinolone susceptible).
 Discussion
The management of rUTI is challenging to pediatricians, emergency department physicians, 
and urologists, particularly for children without anatomic or functional urinary tract disease. 
Currently, no guidelines exist to guide initial evaluation and subsequent treatment of these 
children. Particularly important is the lack of strategies aimed at reducing recurrences. An 
understanding of the underlying factors predisposing patients to rUTI has been elusive and 
thus limits the employment of rational, effective therapies and guidelines. As a result, 
patients with rUTIs are exposed to multiple antibiotic courses which may portend a selection 
to multi-drug resistant organism and more complicated infections. Here we report our early 
experience with a clinical practice entailing 2 complementary therapies to target the known 
reservoirs of uropathogens responsible for rUTI and thus lowering rates of recurrence. In our 
patient cohort, 70% of children who had a history of highly frequent, recurrent UTIs did not 
experience rUTI within the therapeutic period we reviewed.
Our rational design for UTI prevention entails targeted reduction of uropathogenic bacteria 
within the reservoirs in which they reside and blocking their transition from reservoirs into 
the urinary tract. The intestinal and vaginal tracts are known reservoirs for uropathogenic 
bacteria, particularly E. coli, the leading cause of UTI. Hooton et al used molecular and 
antibiotic susceptibility patterns to identify clones of E. coli in the feces and vagina of adult 
healthy women 2 weeks preceding the eventual development of UTI with a matched E. coli 
strain.11 Stapleton et al demonstrated a strong reciprocal relationship between levels of 
vaginal Lactobacilli, vaginal E. coli, and the development of recurrent UTI.12
Probiotics may have a role in reducing uropathogens in rUTI reservoirs. Administration of 
the probiotic yeast S. boulardii to 24 children resulted in a significant decrease in the number 
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of E. coli colonies and appropriately higher counts of S. boulardii in stool specimens.5 A 
randomized study of 41 women diagnosed with UTI demonstrated that, after antimicrobial 
therapy for a UTI, women given Lactobacillus vaginal suppositories were approximately 
50% less likely to develop rUTI than women given a placebo vaginal suppository.13 
Similarly a study in children with VUR also showed that the use of the probiotic 
Lactobacillus acidophilus resulted in a reduction in rUTIs at a rate comparable to the use of 
prophylactic antibiotics.14 These data suggest that the reduction of uropathogen reservoirs 
and replacement by non-uropathogenic flora may have a role in reducing the risk for rUTIs. 
Saccharomyces boulardii has some advantage over Lactobacillus probiotics because of 
resistance to anti-bacterial antibiotics. This characteristic, combined with data on its 
reduction of uropathogenic E. coli in the gut reservoir, was the basis for its inclusion in a 
rUTI prophylactic regimen.
In the past decade and a half, intracellular quiescent bacteria in the bladder epithelium have 
entered into consideration as a source for recurrent UTI. Uropathogenic E. coli rapidly 
replicates in IBCs within the bladder epithelium and creates latent quiescent reservoirs in 
bladder epithelial cells that are viable even after many antibiotics.7 In the murine UTI 
model, quiescent reservoirs of viable bacteria have been noted in the bladder epithelium for 
greater than 3 months after the initial infection with concurrent negative urine cultures.15 
These dormant bacteria have been proposed to serve as one source for recurrent infections. 
Although latent quiescent bacteria in the bladder epithelium have been challenging to 
demonstrate in humans, intracellular bacteria in the form of IBCs have been observed in 
shed bladder epithelial cells within urine of adults and children with UTI, suggesting that 
uropathogens routinely invade the bladder epithelium.6–8 Prolonged fluoroquinolone 
administration capitalizes on the high cell penetration of this antibiotic class to eradicate 
these quiescent communities that may remain viable with shorter antibiotic courses or 
therapy with agents with poor tissue penetration.9
Our observations are limited in several ways. The non-controlled retrospective design limits 
the extent to which important variables were able to be quantified including therapeutic 
compliance and heterogeneity in care including constipation management. This combined 
with the small size limits the applicability to other cohorts. However, given the chronic 
nature of these patient symptoms, the highly significant difference between the total number 
of UTI episodes before and after initiation of therapy in this patient cohort and an increase in 
the interval without an infection and/or its symptoms this treatment regimen has the 
potential to improve the overall quality of life, decrease antibiotic courses and decrease 
health care costs. Based on our observations from this retrospective review, we plan to 
further validate these results with a larger cohort of patients in a prospective, randomized 
trial.
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Table 2
Urinalysis and microbiologic data prior to the start of combined therapy.
Patient
Number
Urinalysis result Predominant Organism Fluoroquinolone
sensitivity
1 1 episode: nitrite and LE + E. coli, K. pneumoniae Sensitive
2 NA E.coli Sensitive
3 NA E.coli NA
4 2 episodes: nitrites and LE + E. coli, P. aeruginosa Sensitive
5 3 episodes: blood and LE + E. coli, K. pneumoniae NA
6 3 episodes: >6 WBC/hpf or LE + E. coli Sensitive
7 5 episodes: blood or nitrites E. coli (including ESBL E. coli) Sensitive
8 4 episodes: blood or nitrite E. coli, K. pneumoniae Sensitive
9 3 episodes: nitrites and LE + E. coli Sensitive
10 3 episodes: blood and LE + E. coli, P. aeruginosa Sensitive
NA = Not Available, LE = Leukocyte esterase
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